| Literature DB >> 19527518 |
Adriana Rojas-Villarraga1, Javier Bayona, Natalia Zuluaga, Santiago Mejia, Maria-Eugenia Hincapie, Juan-Manuel Anaya.
Abstract
BACKGROUND: Alterations in the feet of patients with rheumatoid arthritis (RA) are a cause of disability in this population. The purpose of this research was to evaluate the impact that foot impairment has on the patients' global quality of life (QOL) based on validated scales and its relationship to disease activity.Entities:
Mesh:
Year: 2009 PMID: 19527518 PMCID: PMC2702313 DOI: 10.1186/1471-2474-10-67
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Main Demographic and clinical characteristics in 95 RA patients
| Variables | Percentage |
| Female | 83.1% (79) |
| RF (+) | 70.1% (63/89) |
| Steroid therapy | 72.6% (69) |
| Methotrexate | 80% (76) |
| Chloroquine | 63.1% (60) |
| DMARDS | 35.7% (34) |
| Tumor necrosis factor alpha inhibitor | 15.8% (15) |
| Mean ± SD | |
| Current Age (years) | 52.5 ± 12.4 |
| Age at RA onset (years) | 44 ± 12.4 |
| Duration of RA (years) | 9 ± 7.1 |
| Swollen joints count | 4.9 ± 5.6 |
| Patient global assessment (VAS) | 4.2 ± 2.7 |
| Physician global assessment (VAS) | 4.5 ± 2.3 |
| HAQ | 0.5 ± 0.6 |
| DAS 28 | 3.7 ± 1.5 |
| ESR (mm/hour) | 30.6 ± 21.1 |
| CRP (mg/dl) | 0.9 ± 1.1 |
RF: rheumatoid factor (IU/ml); HAQ: Health Assessment Questionnaire; DAS 28: Disease Activity Score 28; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; VAS: Visual Analogue Scale; DMARDS: Disease Modifying antirheumatic drugs
Main foot abnormalities in a group of 95 patients with RA
| Foot Alterations (N = 78) | % | N |
| Hallux Valgus | 65.3 | (62) |
| Hallux Rigidus | 2.1 | (2) |
| Hammer toe (Hallux) | 0 | (0) |
| Hammer toe (Lesser toes) | 6.3 | (6) |
| Claw toe (Hallux) | 0 | (0) |
| Claw toe (Lesser toes) | 38.9 | (37) |
| Cock-up toe (Hallux) | 1.1 | (1) |
| Cock-up toe (Lesser toes) | 34.7 | (33) |
| Metatarsofalangeal (luxation) | 7.3 | (7) |
| Medial Longitudinal Arch Flattening | 42.1 | (40/93) |
| Transverse Arch Flattening | 25.3 | (24/93) |
| Plantar/Dorsal Hyperqueratosis | 76.8 | (73) |
| Plantar/Dorsal Ulcers | 0 | (0) |
| Hindfoot Valgus | 21.1 | (20/94) |
| Hindfoot Varus | 17.9 | (17/94) |
| Posterior Tibial Disfunction | 2.1 | (2/94) |
| Painful metatarsophalangeal compression positive squeeze test | 46.3 | (44) |
| Forefoot movement pain | 15.8 | (15) |
| Subtalar movement pain | 22.1 | (21) |
| Tibiotalar movement pain | 24.2 | (23) |
| Plantarflexion restriction (Hallux) | 3.2 | (3) |
| Plantarflexion restriction (Lesser toes) | 3.2 | (3) |
| Dorsiflexion restriction (Hallux) | 3.2 | (3) |
| Dorsiflexion restriction (Lesser toes) | 2.1 | (2) |
| Eversion restriction | 26.3 | (25) |
| Inversion restriction | 17.9 | (17) |
| Plantarflexion restriction (Tibiotalar) | 18.9 | (18) |
| Dorsiflexion restriction (Tibiotalar) | 33.7 | (32) |
Foot alterations associated with disability and disease activity risk.
| Foot Deformities and Alterations | Disease Activity (DAS28 > 3.2) | Disability (HAQ II – III) | ||||
| AOR | 95%CI | P | AOR | 95%CI | p | |
| Hallux Valgus | 2.7 | (1–7) | 0.018 | NS | NS | NS |
| Positive Squeeze test | NS | NS | NS | 6.3 | (1.3 – 31) | 0,023 |
| Forefoot movement pain | 14.4 | (1.6 – 133.2) | 0,000 | 16.6 | (4 – 69.3) | 0,000 |
| Subtalar movement pain | 7.2 | (1.6 – 34) | 0,012 | 5.5 | (1.5 – 20.5) | 0,011 |
| Tibiotalar movement pain | 7.9 | (1.7 – 37) | 0.009 | 4.7 | (1.3 – 17.4) | 0.019 |
| Plantarflexion restriction (Tibiotalar) | 14 | (1.7 – 116.1) | 0.014 | 4.5 | (1.2 – 17.1) | 0.025 |
| Dorsiflexion restriction (Tibiotalar) | 4.7 | (1.6 – 14.7) | 0.008 | NS | NS | NS |
AOR: Adjusted odds ratio by age, gender and duration of disease; CI: confidence interval; DAS 28: Disease Activity Score 28; HAQ: Health assessment questionnaire